Drug intelligence / Profile preview

ephedrine + theophylline

Development stage
Discontinued
Lead developer
Eton Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Ephedrine + theophylline is a combination of two small molecule drugs used primarily as a bronchodilator for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). The combination leverages two mechanisms of action: - **Theophylline** is a methylxanthine that acts as a nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to relaxation of bronchial smooth muscle. It also antagonizes adenosine receptors. - **Ephedrine** is a sympathomimetic amine that stimulates both alpha and beta adrenergic receptors by promoting norepinephrine release. This results in bronchodilation through direct smooth muscle relaxation in airways. Historically, this combination was used to manage symptoms like wheezing, shortness of breath, and bronchospasm. However, studies have shown that adding ephedrine to theophylline does not significantly improve efficacy but increases adverse effects such as insomnia, nervousness, tremor, nausea, gastrointestinal complaints, and cardiovascular risks[1][3][5]. As safer alternatives became available (notably inhaled beta-agonists), use declined sharply. This specific dual-drug formulation has largely been discontinued or withdrawn from many markets due to safety concerns[1][9].

Brand names
Franol
Other names
theophylline + ephedrinetheophylline and ephedrineephedrine and theophylline
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)ADOR (Adenosine receptors)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on ephedrine + theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ephedrine + theophylline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call